Ann: Ikon Legal Action - Decision, page-17

While i was not impressed with the original advertisements either, I think the subsequent 3 years of traction in the US and Japanese markets has been outstanding.  We can look across the corporate landscape and seem many corporate stuff ups.

 Australian banks and AMP in the UK

BHP copper plants in WA and US Shale and Sth American mining

the Royal Commission and Financial Institutions 

Insurance companies ripping off clients through worthless contracts

I think CDYs quick action to shut down the campaign down and challenge the delivered product was pretty mild in comparison if we are looking at CEO stuff ups.

Looking back a few years when the MK portfolio was acquired and the Advandgen IP to what is nearly an international product platform in Evolis as well as (near) orphan drug designation I reckon the board ( in the main) and CEO have done a outstanding job. 

not sure I agree with undisclosed "low bar" performance hurdles however i can live with it (i think) in light of the companies developments to date.

So lets put the ikon decsion into perspective.  If that is the worse thing the company can do then I'll remain on-board.  In fact bought 

a few more last week.  Love round numbers.

GLTA (mostly)